
SynAct Pharma Investor Relations Material
Latest events

CMD 2024
SynAct Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from SynAct Pharma
Access all reports
SynAct Pharma AB, develops medicines for acute deterioration in inflammatory diseases. The company's lead product, Synacto®, is a mix of three anti-inflammatory protease inhibitors for the treatment of patients who have recently had a heart attack, have re-opened their old heart wounds due to surgery, or are going to undergo procedures in which blood clotting is needed. SynAct Pharma AB is based in Lund, Sweden.
Key slides for SynAct Pharma


CMD 2024
SynAct Pharma


CMD 2024
SynAct Pharma
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
SYNACT
Country
🇸🇪 Sweden